Abstract:OBJECTIVE:To study whether the expression level of cyclooxygenase-2 (COX-2) is correlated with the proliferation and apoptosis of cancer cells and to study whether the RNA interference technique can be used in anti-cancer gene therapy.METHODS:WBH1, a eukaryotic expression plasmid of shRNA targeting on COX-2, was constructed. Human gastric cancer cells of the line SGC-7901 were cultured and divided into 3 groups: to be transfected with WBH1 or negative control plasmid HK, or used as un-transfected control group. RT-PCR and Western blotting were used to detect the expression of COX-2 mRNA and protein. MTT method was used to detect the proliferation of the cells. The apoptosis of the cells was determined by flow cytometry. Fifteen nude mice were randomly divided into 3 equal groups: 10 to be inoculated subcutaneously with WBH1 plasmid transfected SGC-7901 cells (inhibition group) or negative control plasmid HK transfected SGC-7901 cells, and 5 were used as un-transfected controls. The mice were observed for 4 weeks to observe the survival and the tumorigenesis. Then the mice were killed to take out the tumors. The tumorigenic rate and tumor inhibition rate were evaluated.RESULTS:The proliferation of the SGC-7091 cells transfected with WHB1 plasmid did not changed significantly 24 and 48 hours after the transfection, however, decreased significantly 96 hours and 1 week after (both P < 0.01). The apoptotic rate of the SGC-7091 cells transfected with WHB1 plasmid was 52.28% +/- 17.91%, significantly higher than that of the cells transfected with the control plasmid HK (0.54% +/- 0.16%) and that of the un-transfected cells (0.52% +/- 0.27%, both P = 0.009) without a significant difference between the latter 2 groups (P = 0.998). Four weeks after inoculation the tumorigenic rate was 100% in both the un-transfected control mice and the mice inoculated with negative plasmid HK transfected SGC-7901 cells. There was no significant difference in tumor size between these 2 groups (P = 0.965). The tumorigenic rate of the mice in the inhibition group was 0.4 with an inhibition rate of 89.8%. The tumor weight of the inhibition group was 0.050 g +/- 0.003 g, significantly lighter than those of the control group and the group inoculated with negative plasmid transfected SGC cells (0.490 g +/- 0.017 g and 0.490 g +/- 0.013 g respectively, both P < 0.01).CONCLUSION:Construction of a eukaryotic expression vector expressing the specific shRNA targeting on COX-2, closely related to the proliferation and apoptosis of tumor cells, and transfection of it into the tumor cells helps inhibit the expression of COX-1, thus inhibiting the growth and proliferation of the tumor cells.

Targeting COX-2 potently inhibits proliferation of cancer cells in vivo but not in vitro in cutaneous squamous cell carcinoma

Selective Inhibition of Cyclooxygenase-2 Suppresses the Growth of Pancreatic Cancer Cells in Vitro and in Vivo

Knockdown of Cyclooxygenase-2 Leads to Growth Inhibition and Cell Cycle Arrest in Hepatocellular Carcinoma Cells.

Cyclooxygenase-2 inhibition as a strategy for treating gastric adenocarcinoma.

Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells.

Combined Effects of Cyclooxygenase-1 and Cyclooxygenase-2 Selective Inhibitors on Ovarian Carcinoma in Vivo.

Effects of the Inhibition of Cyclooxygenase-2 on Human Esophageal Cancer Cells: Inhibition of Cell Proliferation and Induction of Apoptosis

Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398.

In Vitro and in Vivo Inhibitory Effect Evaluation of Cyclooxygenase-2 Inhibitors, Antisense Cyclooxygenase-2 Cdna, and Their Combination on the Growth of Human Bladder Cancer Cells.

Anti-cancer Effects of COX-2 Inhibitors and Their Correlation with Angiogenesis and Invasion in Gastric Cancer

The COX-2 Selective Inhibitor-Independent COX-2 Effect on Colon Carcinoma Cells is Associated with the Delta1/Notch1 Pathway

Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia

The Effects of Inhibited the Proliferation by Celecoxib in Human Primary Hepatic Cancer Xenograft of Nude Mice in Vivo

Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells

[The Effects of Selective Cyclooxygenase-2 Inhibitors on the Growth of Gastric Adenocarcinoma].

shRNA-targeted Cyclooxygenase (COX)-2 inhibits proliferation, reduces invasion and enhances chemosensitivity in laryngeal carcinoma cells

The effects of cyclooxygenase-2 gene silencing by siRNA on cell proliferation, cell apoptosis, cell cycle and tumorigenicity of Capan-2 human pancreatic cancer cells.

[Effects of Inhibition of Cyclooxygenase-2 by RNA Interference on Proliferation and Apoptosis of Human Gastric Cancer Cells: an Experimental Study with Human Gastric Cancer Cells and Mice].

Effects of Three Kinds of Selective Cyclooxygenase-2 Inhibitors on the Growth of Hepatocellular Carcinoma

Celecoxib Inhibits Tumor Growth and Angiogenesis in an Orthotopic Implantation Tumor Model of Human Colon Cancer.

Inhibition Effect of NS-398 Via COX-2 Dependent and Independent Mechanisms in Human Pancreatic Cancer Cells